GNLKQ — Genelink Share Price
Last trade - 00:00- $0.01m
- $1.08m
- $2.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -97.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.38 | 8.56 | 7.84 | 4.68 | 2.14 | n/a | n/a | 85.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genelink, Inc. is a supplier of custom oligonucleotides. The Company offers a range of commercially available modifications, fluorescently labeled probes, and specialized probes, such as Molecular Beacons, TaqMan, and Fluorescence resonance energy transfer (FRET), as well as a variety of other molecular biology products, such as linkers, adaptors, deoxyribonucleic acid (DNA) purification and clean-up kits. The Company’s product line of gene detection systems comprises reagents and reagent systems for scientists in the detection of genetic disorders. The Company focuses on triple repeat disorders, which include fragile x, myotonic dystrophy, huntington's disease. It also specializes in the synthesis of ribonucleic acid (RNA) modified oligos, RNA fluorescent probes with quenchers, chimeric oligos containing various combinations of DNA, 2'O methyl or chimerics. The Company serves various industries, including research institutes, pharmaceutical companies and hospitals.
Directors
- Last Annual
- December 31st, 2012
- Last Interim
- September 30th, 2013
- Incorporated
- January 6th, 1995
- Public Since
- March 9th, 2000
- No. of Employees
- 15
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 265,018,689
- Address
- 1 Westchester Plaza,, Suite 126, ELMSFORD, 10523
- Web
- https://www.genelink.com/
- Phone
- +1 4076801150
- Auditors
- Hancock Askew & Co., LLP
Similar to GNLKQ
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 20:46 UTC, shares in Genelink are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Genelink last closed at $0.00 and the price had moved by +3900% over the past 365 days. In terms of relative price strength the Genelink share price has outperformed the S&P500 Index by +3637.06% over the past year.
There is no consensus recommendation for this security.
Find out moreGenelink does not currently pay a dividend.
Genelink does not currently pay a dividend.
Genelink does not currently pay a dividend.
To buy shares in Genelink you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Genelink had a market capitalisation of $0.01m.
Here are the trading details for Genelink:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: GNLKQ
Based on an overall assessment of its quality, value and momentum Genelink is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genelink. Over the past six months, its share price has outperformed the S&P500 Index by +314.06%.
As of the last closing price of $0.00, shares in Genelink were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genelink PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Genelink's management team is headed by:
- Bernard Kasten - CHM
- Michael Smith - CFO
- Robert Ricciardi - CSO